Drug Trial Radar · NCT04037605
Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women
Last checked: Nov 20, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5
Actual
Start
Feb 9, 2020
Primary completion
Jul 24, 2022
Study completion Jun 24, 2026
Sponsor
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 30, 2019
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to 1) determine how hypothalamic-pituitary-adrenal axis (HPA axis) activation occurs with sleep restriction and 2) evaluate how hypothalamic-pituitary-gonadal axis (HPG axis) deactivation occurs with sleep restriction. The investigator will also examine the cognitive function associated with sleep restriction, including food intake and food cravings.
Conditions
- Sleep Restriction
Interventions
Ketoconazole Pill (also known as nizoral)Drug
Ketoconazole pill is taken 4 times per inpatient visit
GanirelixDrug
Ganirelix subcutaneous injection is administered twice per inpatient visit
Dexamethasone PillDrug
Dexamethasone pills is taken twice per inpatient visit
Dexamethasone injectionDrug
Dexamethasone IV injection is given twice per inpatient visit
Cosyntropin Injectable ProductDrug
Cosyntropin injection is given twice per inpatient visit
Recombinant Human Luteinizing Hormone (also known as luveris)Drug
Recombinant Human Luteinizing Hormone is given as 6 IV infusion pulses per inpatient visit
Hydrocortisone Injection (also known as solu-cortef)Drug
Hydrocortisone IV push is given twice per inpatient visit
Gonadorelin (also known as Lutrepulse)Drug
Gonadorelin IV injection is given twice per inpatient visit
Corticorelin (also known as Acthrel)Drug
Corticorelin IV injection is given twice per inpatient visit
Placebo oral tabletDrug
Placebo for Ketoconazole are given 4 times per inpatient visit
Saline SolutionDrug
Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per inpatient visit
Saline solution for injectionDrug
Saline Solution (placebo) for ganirelix subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average Blood Cortisol ConcentrationTime frame: 5 days
- Average Blood Testosterone ConcentrationTime frame: 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Los Angeles Biomedical Research Institute
Torrance, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.